A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion
Phase of Trial: Phase IV
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Central retinal vein occlusion; Retinal oedema
- Focus Therapeutic Use
- Acronyms CENTERA
- Sponsors Bayer
- 11 Sep 2017 Planned End Date changed from 15 Aug 2019 to 15 Sep 2019.
- 11 Sep 2017 Planned primary completion date changed from 15 Aug 2019 to 15 Sep 2019.
- 25 Aug 2016 Planned End Date changed from 1 May 2019 to 1 Aug 2019.